Health Canada has reviewed evidence on the link between glucagon-like peptide-1 (GLP-1) receptor agonists and suicide, self-harm and suicidal/self-harm ideation.
Three-year study shows significant and sustained weight reduction with tirzepatide and a markedly lower risk of progression from prediabetes to type 2 diabetes.